Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion

Acurx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.52

Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.
Cash $9.1M at June 30, 2022, down from $13.1M at Dec 31, 2021.
Phase 2b CDI trial enrollment slower; up to 30 clinical sites being added.
Raised $4.225M via July 2022 direct offering to institutional investor and executives.
Ibezapolstat showed favorable killing kinetics vs vancomycin in lab studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.